UPC CFI 148/2024

Vor dem UPC: Sanofi Group (33 Verfahren)·Zentiva Group (15 Verfahren)

• 2025-12-12
  Infringement ActionÖffentlich

  Zusammenfassung: The Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.

  Rechtsfragen anzeigen (1)

  • Rectification of decisions Rule 353 RoP
• 2025-12-12
  Infringement ActionÖffentlich

  Zusammenfassung: The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.

  Rechtsfragen anzeigen (4)

  • Inventive step (cabazitaxel formulation)
  • Infringement
  • Pharmaceutical patent
  • Counterclaim for revocation
• 2025-09-15
  Infringement ActionÖffentlich

  Zusammenfassung: Munich Local Division order (judge-rapporteur Zigann) following the second interim conference in consolidated infringement proceedings by Sanofi entities against Zentiva, STADA, Dr. Reddy's and Accord Healthcare groups concerning EP 2 493 466 (insulin glargine). The order confirms the oral hearing dates (14-17 October 2025), orders all four counterclaims to be heard together with separate handling of each infringement action, and gives organisational directions for the hearing.

  Rechtsfragen anzeigen (3)

  • Oral hearing scheduling (R. 105.5 RoP)
  • Coordination of joint counterclaims for revocation with multiple infringement actions
  • Insulin glargine / pharmaceutical patent